Ligand Pharmaceuticals | LGND - Loan Capital


Ligand Pharmaceuticals reported $446.9M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agenus USD 153.98M 15.68M Mar/2026
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 1.23B 687.3M Mar/2026
Baxter International USD 8.62B 6M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Enviri Corporation USD 1.56B 26.44M Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 543.51M 1.3M Jun/2026
Intrexon USD 0 198.67M Jun/2024
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 0 0 Mar/2025